Quick Answer
RxSight, Inc. reported Cash and Equivalents of $19.95 million for fiscal year 2025.
RxSight, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $19.95M | +19.4% |
| 2024 | $16.71M | +72.4% |
| 2023 | $9.69M | -18.1% |
| 2022 | $11.83M | -51.4% |
| 2021 | $24.36M | +74.1% |
| 2020 | $13.99M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $29.63M | +77.2% | -26.6% |
| June 30, 2025 | $40.35M | +65.1% | +44.1% |
| March 31, 2025 | $28.00M | -14.2% | +67.6% |
| December 31, 2024 | $16.71M | +72.4% | -0.1% |
| September 30, 2024 | $16.72M | +69.6% | -31.6% |
| June 30, 2024 | $24.45M | +179.3% | -25.1% |
| March 31, 2024 | $32.65M | +196.4% | +236.8% |
| December 31, 2023 | $9.69M | -18.1% | -1.7% |
- RxSight, Inc. showed an increase of +19.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, RxSight, Inc.’s cash and equivalents has grown by 42.6% (from $13.99 million to $19.95 million).
- The most recent figure is from RxSight, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: